SAN FRANCISCO--(BUSINESS WIRE)--Audentes Therapeutics, Inc., an Astellas genetic medicines company, today announced that it has appointed Julie Person as Senior Vice President, Human Resources. In her new role, Julie will assume leadership responsibilities for talent acquisition, HR operations, employee development and company culture initiatives. She will become a member of the Audentes Executive Team, reporting to President and Chief Executive Officer, Natalie Holles.
“Now more than ever, our people are critical to our success,” stated Natalie Holles, President and Chief Executive Officer. “Julie’s track record of building and leading high caliber teams, and her significant experience in organizational design and culture development, will serve as essential components of our future growth strategy. We look forward to Julie’s significant contributions as we expand our team and continue to advance our promising pipeline of genetic medicines.”
With more than 20 years of experience in leading HR roles in the biopharma industry, Julie excels at aligning culture and strategy to influence results. She has led large enterprise transformations that have leveraged her expertise in organizational design, change leadership and HR technology. Julie joins Audentes from Sangamo Therapeutics, Inc. where she served as Head of Human Resources. Prior to Sangamo, Julie was the Global Head of Talent Management at Shire Plc. where she led talent management, culture and employee experience, and also played a key role in the integrations of both Baxalta International Inc. to Shire, and Shire into Takeda Pharmaceutical Company Ltd. Prior to Shire, Julie spent 12 years at McKesson Corp. in various HR roles of increasing responsibility.
“I am excited about joining Audentes at this point in the company’s journey, when the focus on maintaining the company’s unique culture while expanding the scope of our work is so critical for our future success,” said Person. “I am honored to be part of a leadership team that has the capability and commitment to grow the business, cultivate our talent and ultimately deliver transformative genetic medicines to patients.”
About Audentes Therapeutics, Inc.
Audentes Therapeutics, an Astellas company, is developing genetic medicines with the potential to deliver transformative value for patients. Based on our innovative scientific approach and industry-leading internal manufacturing capability and expertise, we have become the Astellas Center of Excellence for the newly created Genetic Regulation Focus Area. We are currently exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown, with plans to expand our focus and geographic reach under Astellas. We are based in San Francisco, with manufacturing and laboratory facilities in South San Francisco and Sanford, North Carolina.
For more information regarding Audentes, please visit www.audentestx.com.
